Please use this identifier to cite or link to this item:
|Title:||Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea||Authors:||Forsyth, Cecily J ;Verner, E.;Grigg, A.||Issue Date:||May-2014||Source:||Volume 55, Issue 5, pp. 1139 - 1143||Journal title:||Leukemia & Lymphoma||Abstract:||Abstract Cyclical thrombocytosis, acquired von Willebrand syndrome, aggressive non-melanoma skin cancers and other hydroxyurea complications have been reported in Philadelphia-negative myeloproliferative neoplasms (MPNs), but their incidence and clinical consequences have not been defined in a large cohort of patients. We conducted a retrospective analysis of 188 consecutive patients with MPNs specifically addressing the incidence of these complications. Cyclical thrombocytosis was documented in 29 patients (15%), the majority of whom were receiving hydroxyurea. Acquired von Willebrand syndrome was identified in 17 of the 84 screened patients (20%), but was not associated with any major bleeding complications. Non-melanoma skin cancers were reported in 51 patients (27%). Hydroxyurea-related fever occurred in nine of 149 patients (6%) who received hydroxyurea. Seventy-three patients (39%) experienced a total of 98 major thrombotic events, with the majority of these occurring prior to or within 3 months of the diagnosis. Cyclical thrombocytosis, acquired von Willebrand syndrome, aggressive non-melanoma skin cancers and other hydroxyurea-related complications are not infrequent in MPNs and have important clinical consequences for management.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1273||DOI:||10.3109/10428194.2013.827788||Pubmed:||https://www.ncbi.nlm.nih.gov/pubmed/23879199||ISSN:||1026-8022||Publicaton type:||Journal Article||Keywords:||Cancer
|Appears in Collections:||Haematology|
Show full item record
checked on Jun 3, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.